Patents by Inventor Michael Charles Hewitt

Michael Charles Hewitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cycloalkylamines as monoamine reuptake inhibitors
    Patent number: 9868718
    Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 16, 2018
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Jianguo Ma, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, John E. Campbell
  • Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors
    Patent number: 9856274
    Abstract: Provided herein are substituted pyrazolopyridine compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 2, 2018
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John Emmerson Campbell, Philip Jones, Michael Charles Hewitt
  • Substituted quinolines as PDE-10 inhibitors
    Patent number: 9834564
    Abstract: Provided herein are Cyclic Nucleotide Phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: December 5, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John Emmerson Campbell, Michael Charles Hewitt, Philip Jones, Linghong Xie
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20170340605
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.
    Type: Application
    Filed: May 10, 2017
    Publication date: November 30, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Daniel J. Burdick, Alexandre Cote, Terry Crawford, Les A. Dakin, Vickie Hsiao-Wei Tsui, Michael Charles Hewitt, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, Anthony F. Romero, Yong Tang, Alexander M. Taylor, Shumei Wang
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20170342067
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.
    Type: Application
    Filed: May 10, 2017
    Publication date: November 30, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Daniel J. Burdick, Alexandre Cote, Terry Crawford, Les A. Dakin, Vickie Hsiao-Wei Tsui, Michael Charles Hewitt, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, Anthony F. Romero, Yong Tang, Alexander M. Taylor, Shumei Wang
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20170340604
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.
    Type: Application
    Filed: May 10, 2017
    Publication date: November 30, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Daniel J. Burdick, Alexandre Cote, Terry Crawford, Les A. Dakin, Vickie Hsiao-Wei Tsui, Michael Charles Hewitt, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, Anthony F. Romero, Yong Tang, Alexander M. Taylor, Shumei Wang
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20170312292
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: April 7, 2017
    Publication date: November 2, 2017
    Inventors: Anthony F. Romero, Steven R. Magnuson, Richard Pastor, Vickie Hsiao-Wei Tsui, Jeremy Murray, Terry Crawford, Daniel J. Burdick, Brian K. Albrecht, Alexandre Cote, Alexander M. Taylor, Christopher G. Nasveschuck, Yves LeBlanc, Michael Charles Hewitt, Kwong Wah Lai, Kevin Chen
  • PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REPUTAKE INHIBITORS
    Publication number: 20170204050
    Abstract: Phenyl-substituted cyclohexylamine derivatives and methods for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
    Type: Application
    Filed: January 30, 2017
    Publication date: July 20, 2017
    Inventors: Liming SHAO, Fengjiang WANG, Scott Christopher MALCOLM, Michael Charles HEWITT, Jianguo MA, Seth RIBE, Mark A. VARNEY, Una CAMPBELL, Sharon Rae ENGEL, Larry Wendell HARDY, Patrick KOCH, Rudy SCHREIBER, Kerry L. Spear
  • BENZO [C] ISOXAZOLOAZEPINE BROMODOMAIN INHIBITORS AND USES THEREOF
    Publication number: 20170079984
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: September 27, 2016
    Publication date: March 23, 2017
    Inventors: Brian K. Albrecht, Michael Charles Hewitt, Victor S. Gehling, Rishi G. Vaswani
  • Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
    Patent number: 9586888
    Abstract: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: March 7, 2017
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Jianguo Ma, Seth Ribe, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, Rudy Schreiber, Kerry L. Spear
  • Bromodomain inhibitors and uses thereof
    Patent number: 9522920
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: December 20, 2016
    Assignee: CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Victor S. Gehling, Jean-Christophe Harmange, Michael Charles Hewitt, Yves Leblanc, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof
    Patent number: 9493483
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: November 15, 2016
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Michael Charles Hewitt, Victor S. Gehling, Rishi G. Vaswani
  • Bromodomain inhibitors and uses thereof
    Patent number: 9422292
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: August 23, 2016
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Victor S. Gehling, Michael Charles Hewitt, Alexander M. Taylor, Jean-Christophe Harmange
  • Multicyclic compounds and methods of use thereof
    Patent number: 9351954
    Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. For example, disclosed herein are compounds having formula (IIa) shown below, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the variables are defined herein. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 31, 2016
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC.
    Inventors: Liming Shao, John Emmerson Campbell, Michael Charles Hewitt, Una Campbell, Taleen G. Hanania
  • HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160102106
    Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
    Type: Application
    Filed: October 15, 2015
    Publication date: April 14, 2016
    Inventors: John Emmerson Campbell, Philip Jones, Michael Charles Hewitt
  • MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160083399
    Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
    Type: Application
    Filed: November 24, 2015
    Publication date: March 24, 2016
    Inventors: Liming SHAO, John Emmerson CAMPBELL, Michael Charles HEWITT, Una CAMPBELL, Taleen G. HANANIA
  • Bromodomain inhibitors and uses thereof
    Patent number: 9249161
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: February 2, 2016
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Victor S. Gehling, Jean-Christophe Harmange, Michael Charles Hewitt, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors
    Patent number: 9249162
    Abstract: Provided herein are compounds of formula A-L-B, and pharmaceutically acceptable salts and stereoisomers thereof, wherein A is ?wherein L, B and R3 are defined herein, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds and compositions provided herein are PDE-10 inhibitors and useful, e.g., for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: February 2, 2016
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John Emmerson Campbell, Philip Jones, Michael Charles Hewitt
  • Heteroaryl Compounds and Methods of Use Thereof
    Publication number: 20150166571
    Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
    Type: Application
    Filed: February 20, 2015
    Publication date: June 18, 2015
    Inventors: John Emmerson Campbell, Michael Charles Hewitt, Philip Jones, Linghong Xie
  • BENZO [C] ISOXAZOLOAZEPINE BROMODOMAIN INHIBITORS AND USES THEREOF
    Publication number: 20150148337
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 28, 2015
    Applicant: CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Michael Charles Hewitt, Victor S. Gehling, Rishi G. Vaswani